Xeris Biopharma Q3 product revenue $29.6M, record; raises cash guidance to $110-120M

Xeris Biopharma Holdings, Inc.

2022-Q3 EPS reported -$0.60 revenue$77,104,000

Net product revenue $29.6M, up 31% pro forma YoY; Gvoke $13.7M (+24%), Keveyis $13.4M, Recorlev $2.5M.
Full-year net product revenue guidance tightened to $105-110M; year-end cash guidance raised to $110-120M.
Net loss $21.8M ($0.16/share) for Q3; cash & investments $93.4M at Sept 30.
Positive Phase 1 topline for subcutaneous levothyroxine (XP-8121); FDA Type C meeting requested.
On track for $50M in synergies by year-end 2022 and cash flow breakeven by year-end 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.